Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41432-024-01012-8 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Urinalysis and perceived effects following 2-week use of a commercial broad-spectrum cannabidiol product.
Exp Clin Psychopharmacol
November 2024
Charlotte's Web.
A growing number of hemp-derived cannabidiol (CBD) products are available with negligible amounts (< 100 ppm) of delta-9-tetrahydrocannabinol (THC) due in part to consumer concerns regarding the risk of positive drug screens. There are, however, no published studies that report whether repeated use of these products may lead to positive urine drug tests for THC. There is also scant research on the effects of these products on physical and mental well-being.
View Article and Find Full Text PDFDiscovering the most impactful treatments for aluminum phosphide cardiotoxicity gleaned from systematic review of animal studies.
Hum Exp Toxicol
October 2024
Department of Toxicology and Pharmacology, Faculty of Pharmacy, and Pharmaceutical Sciences Research Center (PSRC), Tehran University of Medical Sciences, Tehran, Iran.
Article Synopsis
- Aluminum phosphide (AlP) is a dangerous chemical that can cause death by harming heart cells, and there aren't any approved medicines to treat it yet.
- Researchers are looking into different ways to lessen the harmful effects of AlP poisoning, including improving heart function and using various compounds.
- Some treatments like fresh red blood cell transfusion and certain medicines show promise in helping patients, but more research is needed to confirm the best ways to treat AlP poisoning.
Corrigendum to "Safety assessment of female sexual hygiene product containing cannabidiol in New Zealand white rabbit and clinical trial" [Toxicol. Rep. 13 (2024) 101692].
Toxicol Rep
December 2024
Department of Integrative Medicine, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand.
[This corrects the article DOI: 10.1016/j.toxrep.
View Article and Find Full Text PDFCorrection: Cannabidiol ameliorates lipopolysaccharide-induced cardiovascular toxicity by its antioxidant and anti-inflammatory activity via regulating IL-6, Hif1α, STAT3, eNOS pathway.
Mol Biol Rep
August 2024
Mehmet Akif Ersoy University Experimental Animal Production and Experimental Research Center, Burdur, Turkey.
Consensus panel recommendations for the optimization of EPIDIOLEX® treatment for seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.
Epilepsia Open
October 2024
Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
Following the approval of Epidiolex® (cannabidiol; CBD) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC), healthcare professionals (HCPs) have had substantial experience in treating patients with Epidiolex. However, confusion still remains among HCPs, caregivers, and patients regarding dosing, drug interactions, safety monitoring, and differentiation between Epidiolex and nonapproved CBD products. To establish consensus recommendations for Epidiolex treatment optimization in LGS, DS, and TSC, a panel of seven HCPs with expertise in epilepsy was convened.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!